A phase II trial of combination therapy with arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) arising from MDS.
Sekeres, MA; Maciejewski, JP; Erba, HP; Sobecks, R; Advani, A; Nichols, J; Chan, J; Kalaycio, M
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)
48th Annual Meeting of the American-Society-of-Hematology
Conference Start Date
Conference End Date